Zentynel Frontier Investments

Cristián Hernández leads the firm as General Partner, bringing over twenty years of experience investing in and building biotech companies. He has served as CEO or director of multiple biotech ventures and research centers, including Fundación Ciencia & Vida, Nova Mineralis, Ingalfarma, and Phage Labs (per firm website). The full composition of the investment committee beyond Hernández is not publicly detailed.

Zentynel operates as a dedicated venture capital fund manager, not a family office, raising committed capital from external limited partners. It was co-founded by Fundación Ciencia & Vida, a non-profit research institute, and Venturance Alternative Assets, an alternatives manager, combining scientific origination with fund-management discipline. The firm manages successive blind-pool venture funds typical of an institutional GP structure.

Zentynel invests exclusively via direct equity in early-stage operating companies. There is no public evidence of fund-of-fund commitments or LP positions in external venture managers. The model is defined by principal investments with active board-level and operational engagement.

The firm targets early-stage opportunities, typically writing initial checks between US$1 million and US$2 million. It reserves 25–30% of each fund for follow-on investments to support portfolio companies through subsequent financing rounds (per firm website).

Zentynel focuses exclusively on biotech and health-tech; publicly available portfolio data shows no investments outside human health, animal health, agtech, foodtech, or digital-health platforms. Sectors such as enterprise software, fintech, or industrial tech fall outside its mandate.

Portfolio companies originate from Chile, Argentina, Brazil, Uruguay, Mexico, Colombia, the United States, and Europe, reflecting a Latin America-plus strategy that seeks founding teams with regional scientific roots and global commercial ambition. The firm itself is managed from Santiago, Chile.

Fundación Ciencia & Vida is one of the two founding entities behind Zentynel, contributing deep scientific networks and domain expertise that anchor the fund's deal sourcing and technical diligence. Venturance Alternative Assets provides the fund management and alternatives-investing infrastructure. The fund operates independently as an investment manager, drawing on the foundation for non-commercial scientific advisory capacity.